JSAM
MLYS icon

J. Safra Asset Management’s Mineralys Therapeutics MLYS Stock Holding History

J. Safra Asset Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.56K Sell
206
-44
-18% -$1.21K ﹤0.01% 479
2026
Q1 		$6.77K Buy
250
+169
+209% +$4.96K ﹤0.01% 417
2025
Q4 		$2.94K Buy
+81
New +$3.25K ﹤0.01% 501

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

J. Safra Asset Management's MLYS Position: Q2 2026 in Review

J. Safra Asset Management reduced its Mineralys Therapeutics (MLYS) stake by 18% in Q2 2026, selling an estimated $1.21K and leaving 206 shares worth $5.56K. The position accounts for ﹤0.01% of the portfolio, ranked #479.

J. Safra Asset Management first reported a position in MLYS in Q4 2025 and has held it in 3 quarters since. The position peaked at $6.77K in Q1 2026. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • J. Safra Asset Management held 206 shares of Mineralys Therapeutics worth $5.56K as of Q2 2026.
  • J. Safra Asset Management sold 44 Mineralys Therapeutics shares in Q2 2026, an estimated $1.21K.
  • Mineralys Therapeutics made up ﹤0.01% of J. Safra Asset Management's portfolio in Q2 2026, its #479 holding.
  • J. Safra Asset Management first reported a position in Mineralys Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • J. Safra Asset Management's Mineralys Therapeutics position peaked at $6.77K in Q1 2026.
  • 226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on J. Safra Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.